References
- Vander M. A.H., Admiraal P. J.S., Manin V. A.J., et al. Prolonged blood pressure reduction by orally active renin inhibitor RO 42–5892 in essential hypertension. BMJ 1999; 301: 205–10
- Cordero P., Fisher N. D., Moore T. J., et al. Renal and endocrine responses to a renin inhibitor, enalkiren, in normal humans. Hypertension 1991; 17: 510–16
- Wood J. M., Cumin F., Maibaum J. Pharmacology of renin inhibitors and their application to the treatment of hypertension. Pharmacol Ther 1994; 61: 325
- Frishman W. H., Fazailoff A., Lin C., et al. Renin inhibition: A new approach to cardiovascular therapy. J. Clin. Pharmacol. 1994; 34: 873
- Chin A. T., Carini D. J., Vahnson A.L., et al. Non-peptide angiotensin II receptor antagonists: Pharmacology of S-8308. Eur. J. Pharmacol. 1988; 157: 13–21
- Smith R. D., Chia A. T., Wong P. C., et al. Pharmacology of nonpeptide angiotensin II receptor antagonists. Ann Rev Pharmacol Toxicol 1992; 32: 135
- Tsunoda K., Abe K., Hagino T., et al. Hypotensive effect of losartan a neopeptide angiotensin II receptor antagonist in essential hypertension. Ann J. Hyperten 1993; 6: 28–32
- Goldberg M. R., Tanoka W., Barchowsky A., et al. Effect of losartan on blood pressure plasma renin activity and angiotensin II in volunteers. Hypertension 1993; 21: 704–13
- Duty S., Weston A. H. Potassium channel openers. Drugs 1990; 40: 785–91
- Nelson M. T., Quayle J. M. Physiological roles and properties of potassium channels in arterial smooth muscle. Am. J. Physiol. 1995; 268: C535
- Kato K. Haemodynamic and clinical effects and an intravenous potassium channel opener — A review. Eur Heart J. 1993; 14: 40
- Friedel HA, Brogden RN. Pinacidil: a review of its pharmacodynamic and pharmacokinetic properties and its therapeutic potentials in the treatment of hypertension. Drugs 1990; 39: 929–67
- Wilkins M. R., Unwin R. J., Kenny A. J. Endopeptidase — 24.11 and its inhibitors: Potential therapeutic agents for edematous disorders and hypertension. Kidney Int. 1993; 43: 273–85
- Weber R. R. Pharmacokinetic and pharmacodynamic properties of fenoldopam a dopamine 1-receptor agonist in hypertensive patients. Br J Clin Pharmacol. 1988; 25: 17–21
- Deutsch A., Frishman W. H., Sukenik D., et al. Atrial natriuretic peptide and its potential role in pharmacotherapy. J Clin Pharmacol. 1994; 34: 1133
- Elliot W. J., Weber R.R, Nelson K. S., et al. Renal and haemodynamic effects of intravenous fenoldopam versus nitroprusside in severe hypertension. Circulation 1990; 81: 970–77
- Brogden R. D., Sorkin E. M. Kentaserin. Drugs 1990; 40: 903–49
- French J. F., Flynn G. A., Giroux E. L., et al. Characterization of a dual inhibitor of angiotensin I-converting enzyme and neutral endopeptidase. J Pharmacol Exp Ther 1994; 268: 180–186
- Bralet J., Marie C., Mossiat C., et al. Effects of alatriopril, a mixed inhibitor of atriopepddase and angiotensin converting enzyme, on cardiac hypertrophy and hormonal responses in rats with myocardial infarction. Comparison with coptopril. J Pharmacol Exp. Ther 1994; 270: 8–14